Diagnosing and treating eye disorders by Novel Nanotechnology


Journal of Clinical & Experimental Ophthalmology (JCEO) brings articles in all areas related to ophthalmology, neuro-ophthalmology, ocular oncology, clinical ophthalmology, experimental ophthalmology, pediatric ophthalmology, eye diseases, ophthalmic imaging, ophthalmscopy, glaucoma, vision research, cataract, cornea and corneal diseases, ocular microbiology, ophthalmic research .As a member of Publisher International Linking Association, PILA, Longdom Publishing SL’s JCEO follows the Creative Commons Attribution License and Scholars Open Access publishing policies.Journal of Clinical & Experimental Ophthalmology is the Council Contributor Member for Council of Science Editors (CSE) and follows the CSE’s slogan ‘Education, Ethics, and Evidence for Editors.

Dramatic advances in biotechnology are revolutionizing medical science with recent discoveries in cellular and tissue engineering and new drug delivery techniques. There is now great potential to improve medical care by enhancing diagnostic capabilities and substantially expanding therapeutic options. Over the past decade, the pace of biotechnological research has markedly accelerated, especially in the field of ophthalmology, which has never been more exciting or promising. We stand on the threshold of capabilities that will diminish or prevent visual loss. We have proof-of-principle in the applications of novel biosensors, devices, and drug delivery systems for diagnosing and treating eye diseases, which attracts not only scientists and physicians, but also the public. These applications include the measurement of intraocular pressure and the usage of nanoparticles to treat choroidal new vessels, preventing scarring after glaucoma surgery, and treating retinal degenerative disease with gene therapy.

This Research Topic aims to bring together leading researchers to exchange and share their findings on the hot topics of novel nanotechnology for understanding eye physiology, diagnosing eye disorders and treating eye diseases. For example, intravitreal nanoparticles could be used to treat age-related macular degeneration and/or diabetic retinopathy, where conventional delivery systems prove sub-optimal because of factors affecting the drug dynamics . Briefly, personalized diagnosis and therapy originating from nanomedicine should be included in this Research Topic.

Journal of Clinical & Experimental Ophthalmology (JCEO) - Open Access using online manuscript submission, review and tracking systems of OMICS Group for quality and quick review processing.OMICS Group is using Online Review and Editorial Tracking Systems for quality review process. Editorial Tracking System is an online submission and review system, where authors can submit manuscripts and track their progress. Reviewers can download manuscripts and submit their opinions. Editors can manage the whole submission/review/revise/publish process. Publishers can see what manuscripts are in the pipeline awaiting publication. E-mail is sent automatically to concerned persons when significant events occur.

Media contact:


Managing Editor

Journal of Clinical and experimental Ophthalmology

Whatsapp: +1-504-608-2390

Mail ID: ophthalmology@peerjournal.org